NASDAQ:OFIX - Orthofix Stock Price, Price Target & More

Orthofix trades on the NASDAQ under the ticker symbol "OFIX."

Orthofix (NASDAQ:OFIX) issued its earnings results on Monday, April, 30th. The medical device company reported $0.39 EPS for the quarter, beating the Zacks' consensus estimate of $0.36 by $0.03. The medical device company earned $108.71 million during the quarter, compared to the consensus estimate of $107.10 million. Orthofix had a return on equity of 11.08% and a net margin of 3.21%. Orthofix's quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.27 earnings per share. View Orthofix's Earnings History.

Orthofix is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Orthofix.

Orthofix updated its FY18 earnings guidance on Monday, April, 30th. The company provided earnings per share (EPS) guidance of $1.58-1.68 for the period, compared to the Thomson Reuters consensus estimate of $1.62. The company issued revenue guidance of $458-464, compared to the consensus revenue estimate of $460.20 million.Orthofix also updated its Q2 guidance to $0.35-0.37 EPS.

6 brokerages have issued twelve-month price objectives for Orthofix's shares. Their forecasts range from $53.25 to $67.00. On average, they anticipate Orthofix's share price to reach $56.90 in the next year. View Analyst Ratings for Orthofix.

Some companies that are related to Orthofix include Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), OraSure Technologies (OSUR), CryoLife (CRY), Cardiovascular Systems (CSII), K2M Group (KTWO) and Cerus (CERS).

Headlines about OFIX stock have been trending somewhat negative this week, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix earned a daily sentiment score of -0.19 on Accern's scale. They also assigned news coverage about the medical device company an impact score of 46.46 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Orthofix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.14%), Dimensional Fund Advisors LP (4.68%), Segall Bryant & Hamill LLC (3.54%), Millennium Management LLC (3.13%), Diamond Hill Capital Management Inc. (2.28%) and Paradice Investment Management LLC (1.32%). Company insiders that own Orthofix stock include Brad Mason, Bradley V Niemann, Luke T Faulstick, Maria Sainz, Michael Finegan, Raymond Fujikawa, Rice Doug and Ronald A Matricaria. View Institutional Ownership Trends for Orthofix.

OFIX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Millennium Management LLC, Diamond Hill Capital Management Inc., American Century Companies Inc., Segall Bryant & Hamill LLC, California Public Employees Retirement System, Allianz Asset Management GmbH and Citigroup Inc.. Company insiders that have sold Orthofix company stock in the last year include Brad Mason, Bradley V Niemann, Luke T Faulstick, Raymond Fujikawa and Rice Doug. View Insider Buying and Selling for Orthofix.

OFIX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wells Fargo & Company MN, Paradice Investment Management LLC, Tygh Capital Management Inc., Russell Investments Group Ltd., GSA Capital Partners LLP, Argent Capital Management LLC and Summit Global Investments. View Insider Buying and Selling for Orthofix.

Shares of OFIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OFIX stock can currently be purchased for approximately $53.94.

Orthofix has a market capitalization of $1.03 billion and generates $433.82 million in revenue each year. The medical device company earns $6.22 million in net income (profit) each year or $1.62 on an earnings per share basis. Orthofix employs 858 workers across the globe.

Orthofix's mailing address is 7 ABRAHAM DE VEERSTRAAT, WILLEMSTAD P8, . The medical device company can be reached via phone at 599-9-4658525 or via email at [email protected]